|
Options
| ShowHide Related Items >><< - 12/23/20
- Zscaler launches security assessment program following SolarWinds attack
- 11/12/20
- Zscaler appoints Chris Kozup as CMO
- 09/30/20
- Zscaler director sells 20K shares of common stock
- 09/29/20
- JFrog appoints Micheline Nijmeh as chief marketing officer
- 09:56 Today
- Fly Intel: Top five analyst initiations
- 06:07 Today JMP Securities
- Zscaler initiated with an Outperform at JMP Securities
- 01/12/21 Needham
- Zscaler price target raised to $240 from $215 at Needham
- 01/12/21 Credit Suisse
- Zscaler price target raised to $215 from $175 at Credit Suisse
- 12/03/20
- Zscaler raises FY21 EPS view to 37c-38c from 28c-30c, consensus 31c
- 12/02/20
- Zscaler sees Q2 EPS 7c-8c, consensus 7c
- 12/02/20
- Zscaler reports Q1 EPS 14c, consensus 6c
- 12/02/20
- Notable companies reporting after market close
- 09/01/20
- Hackers test security of Trump campaign sites ahead of election, Reuters says
- 12/23/20
- Qualcomm initiation, IAC downgrade among today's top calls on Wall Street
- 12/21/20
- Analysts move to sidelines on SolarWinds following cyberattack
- 12/03/20
- Fly Intel: Wall Street's top stories for Thursday
- 12/03/20
- Fly Intel: Wall Street's top stories at midday
- 12/07/20
- Zscaler put volume heavy and directionally bearish
- 12/04/20
- Unusually active option classes on open December 4th
- 12/02/20
- Zscaler options imply 13.7% move in share price post-earnings
- 09/17/20
- Zscaler put volume heavy and directionally bearish
|
|
Recommendations
| ShowHide Related Items >><< - 12/21/20
- Exelixis announces cabozantinib trial meets co-primary endpoint
- 12/07/20
- Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND
- 12/07/20
- Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND
- 12/02/20
- Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact
- 07:01 Today
- Bristol-Myers: FDA accepts for Priority Review sBLA for Opdivo combination
- 01/11/21
- Bristol-Myers CEO: Our strategy for growth is based on innovation
- 01/11/21
- Illumina announces new and expanded oncology partnerships
- 01/11/21
- Bristol-Myers announces $2B incremental share repurchase plan
- 06:49 Today
- Merck granted FDA approval of Verquvo for cardiosvacular risk reduction
- 01/19/21
- Cocrystal Pharma completes research obligations under Merck agreement
- 01/19/21
- Atea Pharmaceuticals appoints Jayanthi Wolf as SVP, regulatory affairs
- 01/14/21
- Philips. Merck partner on personalized fertility treatment solutions
- 12/16/20
- Merck, Eisai: KEYTRUDA plus LENVIMA showed significant improvement in OS
- 12/10/20
- Biogen submits aducanumab J-NDA to Ministry of Health, Labor and Welfare
- 11/10/20
- Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint
- 11/09/20
- Eisai presents latest BAN2401 data at CTAD
- 12/14/20 William Blair
- Calithera risk/reward attractive into CANTATA readout, says William Blair
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06:51 Today Citi
- Citi opens 'negative Catalyst Watch' on Bristol-Myers
- 12/15/20 Goldman Sachs
- Bristol-Myers upgraded to Conviction Buy from Buy at Goldman Sachs
- 12/09/20 Mizuho
- Pentwater seeks to replace Bristol-Myers Squibb CVR trustee, says Mizuho
- 11/30/20 Citi
- Bristol-Myers price target raised to $77 from $73 at Citi
- 06:51 Today Citi
- Citi opens 'negative Catalyst Watch' on Bristol-Myers
- 01/06/21 Citi
- Citi opens 'positive catalyst watch' on Merck
- 01/05/21 Citi
- Citi boosts Merck target to $105, says may be most undervalued in pharma
- 12/22/20 Mizuho
- Autolus, Arcus among top 2021 oncology picks at Mizuho
- 11/05/20 Jefferies
- Eisai upgraded to Buy from Hold at Jefferies
- 09/08/20 Jefferies
- Eisai downgraded to Hold from Buy at Jefferies
- 01/10/21
- Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B
- 01/10/21
- Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 11/05/20
- Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39
- 11/05/20
- Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25
- 11/05/20
- Bristol-Myers reports Q3 EPS $1.63, consensus $1.49
- 11/04/20
- Notable companies reporting before tomorrow's open
- 10/27/20
- Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78
- 10/27/20
- Merck reports Q3 adjusted EPS $1.74, consensus $1.43
- 10/26/20
- Notable companies reporting before tomorrow's open
- 10/26/20
- Notable companies reporting before tomorrow's open
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 10/05/20
- Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports
- 12/23/20
- Judge rules against White House drug pricing rule, Reuters says
- 12/19/20
- Alphabet, Apple among Barron's 10 Top stocks for 2021, Barron's says
- 11/23/20
- EU seeks easier access to generic medicines, Reuters says
- 11/20/20
- Trump to release new rules aimed at lowering drug prices, WSJ reports
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 11/21/20
- Week in review: How Trump's policies moved stocks
- 11/05/20
- Fly Intel: Pre-market Movers
- 10/08/20
- Cytokinetics plunges following mixed results from heart drug trial
- 12/26/20
- Week in review: How Trump's policies moved stocks
- 12/02/20
- Fly Intel: Wall Street's top stories at midday
- 12/02/20
- Fly Intel: Pre-market Movers
- 11/23/20
- Fly Intel: Wall Street's top stories for Monday
- 08/07/20
- Fly Intel: Wall Street's top stories at midday
- 09:40 Today
- Unusually active option classes on open January 20th
- 01/11/21
- Unusually active option classes on open January 11th
- 01/05/21
- Bristol Myers Squibb call volume above normal and directionally bullish
- 01/04/21
- Bristol Myers Squibb call buyer realizes 25% same-day gains
- 12/23/20
- Merck call volume above normal and directionally bullish
- 10/20/20
- Merck put volume heavy and directionally bearish
- 08/06/20
- Unusually active option classes on open August 6th
- 08/05/20
- Merck call volume above normal and directionally bullish
|
|
Hot Stocks
| ShowHide Related Items >><< - 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/30/20
- CN completes U.S. federal requirement to operate Positive Train Control
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/24/20
- North American rail traffic rose 1.9% in week ended December 19
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/24/20
- North American rail traffic rose 1.9% in week ended December 19
- $215.74 /
+4.045 (+1.91%) - 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/24/20
- North American rail traffic rose 1.9% in week ended December 19
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/24/20
- North American rail traffic rose 1.9% in week ended December 19
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/10/21
- Fly Intel: Top five weekend stock stories
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 01/14/21
- North American rail traffic rose 3% in the week ended January 9
- 01/07/21
- North American rail traffic rose 1.3% in the week ended January 2
- 12/31/20
- North American rail traffic rose 7% in week ended December 26
- 12/24/20
- North American rail traffic rose 1.9% in week ended December 19
- 09:01 Today Scotiabank
- Canadian National downgraded to Sector Perform from Outperform at Scotiabank
- 01/13/21 Barclays
- Canadian National upgraded to Equal Weight from Underweight at Barclays
- 01/11/21 Bernstein
- Canadian National upgraded to Outperform from Market Perform at Bernstein
- 01/11/21 Citi
- Canadian National price target raised to $127 from $110 at Citi
- 09:01 Today Scotiabank
- Canadian Pacific downgraded to Sector Perform from Outperform at Scotiabank
- 01/19/21 CIBC
- Canadian Pacific price target raised to C$500 from C$490 at CIBC
- 01/11/21 Citi
- Canadian Pacific price target raised to $430 from $355 at Citi
- 12/17/20 National Bank
- Canadian Pacific price target raised to C$445 from C$433 at National Bank
- 07:18 Today Susquehanna
- Railroad recovery expected to continue in 2021, says Susquehanna
- 01/11/21 Citi
- CSX price target raised to $105 from $87 at Citi
- 12/10/20 Morgan Stanley
- Morgan Stanley downgrades CSX to Underweight with bar raised too high
- 12/10/20 Morgan Stanley
- CSX downgraded to Underweight from Equal Weight at Morgan Stanley
- $215.74 /
+4.045 (+1.91%) - 01/15/21 Raymond James
- Kansas City Southern price target raised to $245 from $210 at Raymond James
- 01/12/21 JPMorgan
- Kansas City Southern price target raised to $204 from $199 at JPMorgan
- 01/11/21 Citi
- Kansas City Southern price target raised to $250 from $220 at Citi
- 12/10/20 Morgan Stanley
- Morgan Stanley downgrades CSX to Underweight with bar raised too high
- 07:18 Today Susquehanna
- Railroad recovery expected to continue in 2021, says Susquehanna
- 01/13/21 Baird
- Norfolk Southern upgraded to Outperform with $286 price target at Baird
- 01/12/21 Baird
- Norfolk Southern upgraded to Outperform from Neutral at Baird
- 01/11/21 Citi
- Norfolk Southern price target raised to $290 from $250 at Citi
- 07:18 Today Susquehanna
- Railroad recovery expected to continue in 2021, says Susquehanna
- 01/15/21 Raymond James
- Union Pacific price target raised to $250 from $220 at Raymond James
- 01/12/21 JPMorgan
- Union Pacific price target raised to $216 from $212 at JPMorgan
- 01/11/21 Bernstein
- Union Pacific upgraded to Outperform from Market Perform at Bernstein
- 10/20/20
- Canadian National reports Q3 EPS $C$1.38 versus $C1.66 in Q319
- 07/21/20
- Canadian National reports Q2 EPS C$1.28, consensus C$1.26
- 10/20/20
- Canadian Pacific sees at least mid-single-digit adjusted EPS growth in 2020
- 10/20/20
- Canadian Pacific reports Q3 adjusted EPS C$4.12 vs. C$4.61 last year
- 07/22/20
- Canadian Pacific sees adjusted diluted EPS growth year over year
- 07/22/20
- Canadian Pacific reports Q2 adjusted EPS C$4.07 vs. C$4.30 last year
- 10/21/20
- CSX reports Q3 EPS 96c, consensus 92c
- 10/21/20
- Notable companies reporting after market close
- 07/22/20
- CSX reports Q2 EPS 65c, consensus 64c
- 07/22/20
- Notable companies reporting after market close
- $215.74 /
+4.045 (+1.91%) - 12/03/20
- Kansas City Southern says Q4 revenue-to-date down 5%
- 10/16/20
- Kansas City Southern reports Q3 adj. EPS $1.96, consensus $1.90
- 10/15/20
- Notable companies reporting before tomorrow's open
- 10/15/20
- Notable companies reporting before tomorrow's open
- 10/28/20
- Norfolk Southern reports Q3 adjusted EPS $2.51, consensus $2.38
- 10/27/20
- Notable companies reporting before tomorrow's open
- 10/27/20
- Notable companies reporting before tomorrow's open
- 10/09/20
- Norfolk Southern sees Q3 railway operating revenues of about $2.5B
- 10/22/20
- Union Pacific reports Q3 EPS $2.01, consensus $2.05
- 10/21/20
- Notable companies reporting before tomorrow's open
- 10/21/20
- Notable companies reporting before tomorrow's open
- 07/23/20
- Union Pacific reports Q2 EPS $1.67, consensus $1.55
- $215.74 /
+4.045 (+1.91%) - 11/10/20
- Kansas City Southern potential bidders have moved on, CNBC reports
- 09/09/20
- Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says
- 09/09/20
- Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says
- 09/02/20
- Blackstone, GIP make bid to buy Kansas City Southern, WSJ says
- 11/13/20
- Norfolk Southern, ViacomCBS highlighted by Dealreporter amid 'interesting' 13Fs
- 01/09/21
- Some century-old stocks still deliver, Barron's says
- 08/14/20
- Union Pacific issues second spot rate increase in California, JOC.com reports
- 10/21/20
- Fly Intel: After-Hours Movers
- $215.74 /
+4.045 (+1.91%) - 09/10/20
- Fly Intel: Wall Street's top stories for Thursday
- 09/10/20
- Fly Intel: Wall Street's top stories at midday
- 09/09/20
- Fly Intel: After-Hours Movers
- 09/02/20
- Fly Intel: Wall Street's top stories for Wednesday
- 10/22/20
- Fly Intel: Pre-market Movers
- 10/22/20
- Early notable gainers among liquid option names on October 22nd
- 09/15/20
- CSX call volume above normal and directionally bullish
- 09/04/20
- CSX put volume heavy and directionally bearish
- 07/31/20
- CSX call volume above normal and directionally bullish
- $215.74 /
+4.045 (+1.91%) - 07/31/20
- Kansas City Southern bid could be valued over $21B with debt, WSJ reports
- 08/27/20
- Unusually active option classes on open August 27th
- 11/10/20
- Union Pacific put volume heavy and directionally bearish
- 08/03/20
- Union Pacific put volume heavy and directionally bearish
|
|
General news
| |
|
Recommendations
|
Barclays analyst Rishika… ShowHide Related Items >><< - 12/17/20 Morgan Stanley
- Flughafen Zuerich price target raised to CHF 169 from CHF 164 at Morgan Stanley
- 12/04/20 Deutsche Bank
- Flughafen Zuerich price target raised to CHF 182 from CHF 157 at Deutsche Bank
- 11/30/20 UBS
- Flughafen Zuerich downgraded to Neutral from Buy at UBS
- 11/25/20 Morgan Stanley
- Flughafen Zuerich price target raised to CHF 164 from CHF 137 at Morgan Stanley
|